Wesbanco Bank Inc. Cuts Position in Novo Nordisk A/S $NVO

Wesbanco Bank Inc. cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 55.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,520 shares of the company’s stock after selling 97,165 shares during the period. Wesbanco Bank Inc.’s holdings in Novo Nordisk A/S were worth $4,246,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Prospera Financial Services Inc grew its stake in Novo Nordisk A/S by 11.3% in the 3rd quarter. Prospera Financial Services Inc now owns 420,795 shares of the company’s stock valued at $23,351,000 after purchasing an additional 42,789 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in shares of Novo Nordisk A/S by 32.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 232,565 shares of the company’s stock worth $12,905,000 after buying an additional 57,043 shares during the last quarter. Western Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 88.1% in the 3rd quarter. Western Wealth Management LLC now owns 9,864 shares of the company’s stock worth $547,000 after buying an additional 4,619 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in Novo Nordisk A/S by 14.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 565,007 shares of the company’s stock valued at $31,352,000 after buying an additional 71,283 shares during the period. Finally, RFG Advisory LLC increased its holdings in Novo Nordisk A/S by 3.0% during the third quarter. RFG Advisory LLC now owns 53,968 shares of the company’s stock worth $2,995,000 after buying an additional 1,567 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Morgan Stanley reissued an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Stock Down 0.7%

Novo Nordisk A/S stock opened at $49.04 on Wednesday. The firm has a 50 day simple moving average of $53.66 and a 200 day simple moving average of $53.42. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The firm has a market capitalization of $218.96 billion, a price-to-earnings ratio of 14.13 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Hims & Hers pulled its compounded semaglutide product after regulatory pressure, giving Novo a near‑term competitive reprieve. Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
• Positive Sentiment: Novo filed a U.S. patent lawsuit versus Hims over Wegovy copies, signaling aggressive defense of its IP and pricing power. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Positive Sentiment: Market reaction shows competitors’ setbacks can boost Novo’s position in the obesity/GLP‑1 market. Hims & Hers Stock Plunges While Novo Nordisk Gains
• Neutral Sentiment: Company insiders and executives recently reported share transactions (disclosure filing). Watch insider activity but it’s not a directional catalyst by itself. Trading in Novo Nordisk shares by board members, executives and associated persons
• Neutral Sentiment: Zacks highlights why NVO is a trending stock — useful for sentiment tracking but not a direct fundamental driver. Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
• Negative Sentiment: Zacks Research downgraded NVO from “hold” to “strong sell,” adding immediate analyst pressure and signaling lower conviction. Zacks.com
• Negative Sentiment: The FDA told Novo that a TV ad for the Wegovy pill contained false or misleading claims, and requested corrective action — a regulatory hit that raises compliance risk and reputational scrutiny. FDA says Novo Nordisk’s TV ad for obesity pill includes ‘false or misleading’ claims
• Negative Sentiment: Macro/regulatory concerns and weaker 2026 guidance have triggered questions about Novo’s GLP‑1 moat and valuation, pressuring sentiment and multipliers. Regulatory Pressure Tests Novo Nordisk’s GLP 1 Moat And Valuation
• Negative Sentiment: Several analyst/SA pieces flag a sharp slowdown in EPS growth and weak 2026 guidance, elevating downside risk and technical sellers. Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop?

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.